Stocktoria

bioAffinity Technologies, Inc. BIAF

Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research · website · IPO 2022-08-26

bioAffinity Technologies, Inc. financials (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Revenue$6.2M$9.4M$7.9M$6.9M
Gross profit$4,336
R&D expense$1.4M$1.5M$1.5M$1.4M$1.0M
SG&A expense$9.9M$9.9M$6.8M$2.5M$1.1M
Operating income-$10.6M-$9.0M-$8.0M-$4.0M-$2.2M
Interest expense$37,125$2.5M$1.0M
Income tax$44,042$11,650$20,993$2,459$1,950
Net income-$14.9M-$9.0M-$7.9M-$8.2M-$6.3M
EPS (diluted)$-8.66$-22.50$-0.91$-1.81
Operating cash flow-$9.3M-$7.3M-$6.0M-$4.1M-$2.0M
Free cash flow-$9.4M-$7.3M-$6.1M-$4.3M
Cash & equivalents$6.4M$1.1M$2.8M$11.4M$1.4M
Inventory$53,548$27,608$18,484$5,540
Total assets$11.0M$6.5M$8.2M$12.2M$1.5M
Total liabilities$3.7M$3.9M$3.4M$1.1M$13.2M
Shareholders' equity$7.3M$2.6M$4.9M$11.0M-$15.8M

Source: SEC EDGAR filings · CIK 0001712762 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.